Stockreport

Cardiol Therapeutics Touts Phase III MAVERIC Timeline for CardiolRx at TD Cowen Healthcare Conference [Yahoo! Finance]

Cardiol Therapeutics Inc. - Class A Common Shares  (CRDL) 
PDF top-line readout in H2 ; the study uses an enrichment design that withdraws IL-1 blockade to increase placebo recurrence and the FDA has granted Orphan Drug Designation [Read more]